Borgeson Blake
- SEC CIK
- 0001856094
In the past year, 10 open-market sale filings worth $4.10M and no purchases.
Current role at each company
- RXRX Recursion Pharmaceuticals, Inc.Directoras of Sep 2, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $4.10M
- 10 filings
- Net
- −$4.10M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Borgeson Blake as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2023 (view filing) | Apr 18 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $5.93 | −$52.7K | −0.1%7.56M after | |
| Apr 6, 2023 (view filing) | Apr 4 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $6.53 | −$58.0K | −0.1%7.57M after | |
| Mar 23, 2023 (view filing) | Mar 21 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $7.40 | −$65.7K | −0.1%7.58M after | |
| Mar 9, 2023 (view filing) | Mar 7 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $8.33 | −$74.0K | −0.1%7.59M after | |
| Feb 23, 2023 (view filing) | Feb 21 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $7.73 | −$68.7K | −0.1%7.59M after | |
| Feb 9, 2023 (view filing) | Feb 7 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $8.81 | −$78.3K | −0.1%7.60M after | |
| Jan 26, 2023 (view filing) | Jan 24 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $8.71 | −$77.4K | −0.1%7.61M after | |
| Jan 12, 2023 (view filing) | Jan 10 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $7.69 | −$68.3K | −0.1%7.62M after | |
| Dec 29, 2022 (view filing) | Dec 27 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $7.25 | −$64.4K | −0.1%7.63M after | |
| Dec 15, 2022 (view filing) | Dec 13 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $8.96 | −$79.6K | −0.1%7.64M after | |
| Dec 1, 2022 (view filing) | Nov 29 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −8.88K | $8.75 | −$77.7K | −0.1%7.65M after | |
| Nov 18, 2022 (view filing) | Nov 16 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −17.8K | $11.12 | −$197.6K | −0.2%7.65M after | |
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Borgeson BlakeDirector | SSaleClass A Common Stock | −9.63K | $18.03 | −$173.5K | −0.1%7.65M after | |
| Dec 23, 2021 (view filing) | Dec 21 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −9.63K | $18.75 | −$180.5K | −0.1%7.66M after | |
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −9.63K | $20.31 | −$195.5K | −0.1%7.67M after | 3 lots |
| Nov 22, 2021 (view filing) | Nov 18 | 4 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −9.63K | $18.91 | −$182.0K | −0.1%7.68M after | 2 lots |